The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.
about
Sphingosine 1-phosphate receptor modulators in multiple sclerosisFingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapyThe clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in ratArray data extractor (ADE): a LabVIEW program to extract and merge gene array data.Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects.Sphingosine 1-Phosphate Receptors: Do They Have a Therapeutic Potential in Cardiac Fibrosis?A sphingosine-1-phosphate receptor type 1 agonist, ASP4058, suppresses intracranial aneurysm through promoting endothelial integrity and blocking macrophage transmigrationMammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget.Vascular and Immunobiology of the Circulatory Sphingosine 1-Phosphate Gradient.Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration.ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profileOzanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.(7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acids as S1P1 Functional AntagonistsDesensitization by progressive up-titration prevents first-dose effects on the heart: guinea pig study with ponesimod, a selective S1P1 receptor modulatorSphingolipid metabolites in inflammatory disease.Characterization of dose-response for count data using a generalized MCP-Mod approach in an adaptive dose-ranging trial.AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple SclerosisDose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.Implication of sphingosin-1-phosphate in cardiovascular regulation.Design, Synthesis, and In Vitro and In Vivo Evaluation of an (18)F-Labeled Sphingosine 1-Phosphate Receptor 1 (S1P1) PET Tracer.Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery.Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.Lysophospholipid receptor activation of RhoA and lipid signaling pathways.Fingolimod for the treatment of relapsing multiple sclerosis.Modulators of the Sphingosine 1-phosphate receptor 1.Novel therapeutic options for multiple sclerosis.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures.The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination.Implementation of highly sophisticated flow cytometry assays in multicenter clinical studies: considerations and guidance.Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.Sphingosine 1-phosphate receptor 1 agonists: a patent review (2013-2015).Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators.Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism.Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases.
P2860
Q26799440-1B3F4F83-C3DE-4026-9FDF-DEF93D5E7703Q27011473-8A2472A2-B330-47B8-AD76-82AF75E02A0DQ28484640-43C246D1-FC84-43AA-A5ED-72FF0CE6941CQ30704168-816A78D0-25C9-46C2-9AC2-A635A5FCBAB4Q33593619-D54E955A-E4A0-43CE-92BC-8752E43EC85AQ33753317-90E76275-2577-42FC-A897-52C0389ED763Q33784217-F23E00E0-86EC-47DE-B27C-C276F9DCC910Q33829692-FFD97AF8-8C4B-4823-951A-DD3066563397Q33880223-98568AC9-5A3E-4DEF-90F2-1CDE40CC1FD2Q34364844-51A40B1E-1743-4D75-9942-C0009C8C78C5Q34396876-A6BFC8E7-8E86-44CE-9824-0D8DC9994728Q34408450-E4A31F47-7E5D-44D8-9175-490E6976AA38Q34518822-852B8450-8692-4473-A356-1C1DD2850A50Q34699022-46BA0159-B043-4293-9396-B1ECB188BD39Q34699039-E0D0BC97-42D4-4AC1-9939-C9257E9D6412Q34999097-E7E52F1E-68FE-42DE-A12F-9873AB01D1AFQ35061720-E66CCF3E-DF92-4908-B377-4A797A17F30DQ35665759-1FD1D91C-7AD2-4A6D-ABF7-A05D71BA01F3Q35826151-D28123A2-B6A9-4D69-9E77-7193AD09CBE6Q36620247-5DE4B657-FBFB-4864-8714-B0AD77C47832Q36898368-880A9D43-DD4D-4E58-BE97-1D1D06F013FDQ37388254-D3612B28-E9EF-4BED-B538-BBF588D42C3AQ37551932-11DD2D83-AE50-43E2-9CD4-D766D22B512CQ37675273-3F8B3580-A775-44B3-AE59-73BADD6E8A1AQ38044174-24A12EED-22BC-46B0-A75F-3C2DDF02817EQ38112209-3C2465B9-A945-4712-8325-E6727C7B030EQ38152543-B71D6185-3BC0-419F-87F7-ADD91E0B2A41Q38170129-C84EB5AA-1A07-4FE7-B296-2B1BA763FE29Q38172961-8F36947A-D0BA-4B51-8C8A-1A9F5FD7F9B7Q38303665-8D21FECE-EFAD-45D8-9467-A79E8F902964Q38368852-026FEFEF-545A-422B-86B1-AEFB046A8D88Q38516622-B25964FB-C424-4EDB-A47C-06B45674D2A6Q38534132-305A63DA-A137-485A-873F-3141FE0AB00FQ38622668-D107E1C4-114A-4D51-9586-6C80B2205BDCQ38753877-F3399312-BB01-499A-9F78-85D5D4F1A3F4Q38762603-4830F95D-FDF7-45CE-9ED4-305988D57912Q38850104-2351D10E-90D7-41E4-9585-A004C5632766Q38915115-82EB9C18-DCC7-4D0F-9518-98E104B5C810Q38966334-BB41065F-CB82-4981-A1A9-5B938653E327Q39021621-0CB94BAB-051C-46CC-A7CF-0BDB27713C09
P2860
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The selective sphingosine 1-ph ...... pecific effects on heart rate.
@ast
The selective sphingosine 1-ph ...... pecific effects on heart rate.
@en
type
label
The selective sphingosine 1-ph ...... pecific effects on heart rate.
@ast
The selective sphingosine 1-ph ...... pecific effects on heart rate.
@en
prefLabel
The selective sphingosine 1-ph ...... pecific effects on heart rate.
@ast
The selective sphingosine 1-ph ...... pecific effects on heart rate.
@en
P2093
P2860
P1476
The selective sphingosine 1-ph ...... pecific effects on heart rate.
@en
P2093
A Groenewegen
A Vitaliti
B Nuesslein-Hildesheim
E Wallström
K Hinterding
M Rosenberg
P2860
P304
P356
10.1111/J.1476-5381.2012.02061.X
P407
P577
2012-11-01T00:00:00Z